USSTOCK.TODAY
Weekend. Closed
Log in Sign up

Lixte Biotechnology Holdings Inc(LIXT) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today

Halted
Trading Halted Since 2026-07-17: Trading has been halted. It may resume, and prices shown reflect the last trading day.
LIXT
LIXT
Halted
Lixte Biotechnology Holdings Inc
$7.21
-0.46 ▼ -6.00%

Full metrics table

Index ⓘ -P/E ⓘ -EPS (ttm) ⓘ -1.12Insider Own ⓘ 12.02%Shs Outstand ⓘ 17.4MPerf Week ⓘ 8.42%
Market Cap ⓘ 0.13BForward P/E ⓘ -EPS next Y ⓘ -Insider Trans ⓘ -Shs Float ⓘ 15.3MPerf Month ⓘ 2.41%
Enterprise Value ⓘ 0.12BPEG ⓘ -EPS next Q ⓘ -Inst Own ⓘ 4.21%Short Float ⓘ 2.52%Perf Quarter ⓘ 135.24%
Income ⓘ -0.01BP/S ⓘ -EPS this Y ⓘ -Inst Trans ⓘ -21.49%Short Ratio ⓘ 1.71Perf Half Y ⓘ 84.87%
Sales ⓘ 0.00BP/B ⓘ 10.56EPS next 5Y ⓘ -ROA ⓘ -116.7%Short Interest ⓘ 0.39MPerf YTD ⓘ 83.46%
Book/sh ⓘ 0.68P/C ⓘ 38.57EPS past 3/5Y ⓘ 31.98% 15.39%ROE ⓘ -158.69%52W High ⓘ -13.93% ($8.38)Perf Year ⓘ 256.93%
Cash/sh ⓘ 0.19P/FCF ⓘ -Sales past 3/5Y ⓘ -ROIC ⓘ -85.93%52W Low ⓘ 463.28% ($1.28)Perf 3Y ⓘ 22.62%
Dividend Est. ⓘ -EV/EBITDA ⓘ -EPS Y/Y TTM ⓘ 22.5%Gross Margin ⓘ -Volatility(W/M) ⓘ 13% 12.19%Perf 5Y ⓘ -77.47%
Dividend TTM ⓘ -EV/Sales ⓘ -Sales Y/Y TTM ⓘ -Oper. Margin ⓘ -ATR (14) ⓘ 0.82Perf 10Y ⓘ -51.93%
Dividend Ex-Date ⓘ -Quick Ratio ⓘ 2.78EPS Q/Q ⓘ 37.9%Profit Margin ⓘ -RSI (14) ⓘ 54.44Recom ⓘ -
Dividend Gr. 3/5Y ⓘ -Current Ratio ⓘ 2.78Sales Q/Q ⓘ -SMA20 ⓘ 1.66% ($7.09)Beta ⓘ 1.26Target Price ⓘ -
Payout ⓘ -Debt/Eq ⓘ 0.13Earnings ⓘ -SMA50 ⓘ 23.69% ($5.83)Rel Volume ⓘ 2.72Prev Close ⓘ $7.67
Employees ⓘ 3LT Debt/Eq ⓘ 0.06EPS/Sales Surpr. ⓘ -SMA200 ⓘ 67.25% ($4.31)Avg Volume(3M) ⓘ 0.23MPrice ⓘ $7.21
IPO ⓘ 2007/9/21Option/Short ⓘ No/YesTrades ⓘ 3776Volume ⓘ 613,903Change ⓘ -6%
Company
LIXT LIXTLixte Biotechnology Holdings Inc | NASD | Biotechnology Deep dive

🔬 Linnaeus Biosciences (LIXT) is a US-based clinical-stage oncology drug developer focused on novel cancer therapies. Centered on its lead candidate LBT-100, which inhibits protein phosphatase 2A (PP2A), the company pursues a precision oncology strategy that disrupts tumor cell DNA repair mechanisms and enhances immune response. Through collaborations with major cancer centers and large pharmaceutical companies, Linnaeus Biosciences is expanding its clinical pipeline.

Quote

Over the past 1 year, on the higher side

14% below its 1-year high.

Now $7.21
52w low$1.2852w high$8.38
52W Range84%
Volume ⓘ 613,903

Traded more than usual. That is 272% of its average volume.

D
Overall · many cautions
We judged 3 of the 8 questions below. 2 need caution.
No data for growth, valuation, earnings, outlook, dividends, or not applicable.
ETFs holding this stock 3 ETFs

Multiple ETFs hold this stock, but only a sliver

Buying this ETF gives you exposure to this stock as well.

Peer comparison Biotechnology

It ranks #339 of 599 in the industry

Based on market cap of $125M.

FAQ

FAQ

What kind of company is LIXT?

LIXT belongs to the Healthcare sector and operates in the Biotechnology industry.

What is the market cap of LIXT?

The market cap of LIXT is approximately $125M, ranking 4,460 within its sector.

What is the 52-week high and low for LIXT?

LIXT has recorded a 52-week high of $8.38 and a low of $1.28.

Telegram KakaoTalk
Briefs · earnings · signals, first Telegram · KakaoTalk channels